IL301634A - Human mouse models for evaluating immune cell therapy - Google Patents
Human mouse models for evaluating immune cell therapyInfo
- Publication number
- IL301634A IL301634A IL301634A IL30163423A IL301634A IL 301634 A IL301634 A IL 301634A IL 301634 A IL301634 A IL 301634A IL 30163423 A IL30163423 A IL 30163423A IL 301634 A IL301634 A IL 301634A
- Authority
- IL
- Israel
- Prior art keywords
- hours
- cells
- cell
- mouse
- human
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4212—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0387—Animal model for diseases of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Environmental Sciences (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063083016P | 2020-09-24 | 2020-09-24 | |
| US202063083003P | 2020-09-24 | 2020-09-24 | |
| PCT/US2021/051734 WO2022066894A1 (en) | 2020-09-24 | 2021-09-23 | Humanized mouse models for assessing immune cell therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL301634A true IL301634A (en) | 2023-05-01 |
Family
ID=80845843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL301634A IL301634A (en) | 2020-09-24 | 2021-09-23 | Human mouse models for evaluating immune cell therapy |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12196744B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4216971A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023542539A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230074758A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021347320A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3196823A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL301634A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022066894A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11959925B2 (en) | 2017-04-17 | 2024-04-16 | The Jackson Laboratory | Method of determining toxicity of an immunomodulatory drug for use in humans |
| WO2023060126A1 (en) * | 2021-10-06 | 2023-04-13 | Dana-Farber Cancer Institute, Inc. | Engineered cytokine receptors for tunable adoptive cell therapy |
| WO2024029561A1 (ja) * | 2022-08-02 | 2024-02-08 | 学校法人東海大学 | 担がん-免疫不全非ヒト動物、これを用いた供試物質に関するがん免疫応答評価方法 |
| CN117686676B (zh) * | 2023-12-15 | 2025-05-30 | 扬州大学 | 一种基于多水平生物标志物响应法评价水中污染物转代生物效应的方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9100481D0 (en) | 1991-01-10 | 1991-02-20 | Inst Nat Sante Rech Med | Genetically engineered mice |
| US7105158B1 (en) | 1992-11-16 | 2006-09-12 | The Corporation Of Mercer University | Methods of administering microencapsulated materials for immune modulated diseases |
| FR2827302B1 (fr) | 2001-07-13 | 2003-10-10 | Genoway | Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations |
| WO2006007529A2 (en) | 2004-07-01 | 2006-01-19 | University Of Pittsburgh Of The Commonwealth System For Higher Education | Immunosuppressive exosomes |
| JP2007244268A (ja) | 2006-03-15 | 2007-09-27 | Osaka Prefecture Univ | イヌの造血前駆細胞を認識するモノクローナル抗体の製造方法 |
| EP1878342A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
| CN101715485A (zh) | 2007-04-06 | 2010-05-26 | 国际干细胞公司 | 源于人单性生殖胚泡的患者特异性干细胞系 |
| WO2011036308A1 (en) | 2009-09-28 | 2011-03-31 | Theramab Gmbh | Method for preclinical testing of immunomodulatory drugs |
| EP4502152A3 (en) | 2009-10-06 | 2025-04-30 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
| CN102971420B (zh) | 2010-04-14 | 2016-10-26 | 哈伦实验室有限公司 | 无毛nod scid小鼠 |
| EP2422618A1 (en) * | 2010-08-27 | 2012-02-29 | Technologie Integrale Ltd. | Animal model for the evaluation of the efficacy of an HIV vaccine |
| JP2014509841A (ja) | 2011-01-18 | 2014-04-24 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 癌を治療するための組成物および方法 |
| PT4233537T (pt) | 2011-02-15 | 2025-09-08 | Regeneron Pharma | Ratinhos humanizados para m-csf e utilizações dos mesmos |
| WO2013086019A1 (en) | 2011-12-06 | 2013-06-13 | Massachusetts Institute Of Technology | Use of humanized mice to determine toxicity |
| CN103304669A (zh) | 2012-03-12 | 2013-09-18 | 复旦大学 | 人源化肿瘤免疫细胞因子tntil2及其制备方法和用途 |
| EP4063391A1 (en) | 2012-07-25 | 2022-09-28 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
| DK4389764T3 (da) | 2012-11-05 | 2026-04-13 | Regeneron Pharma | Genetisk modificerede gnavere og fremgangsmåder til anvendelse heraf |
| EP2976641B1 (en) | 2013-03-22 | 2018-01-03 | Imperial Innovations Ltd | In vitro method for assessing cytokine storm responses |
| TWI810145B (zh) * | 2015-06-23 | 2023-08-01 | 杰克森實驗室 | 具有病患衍生之異種移植物之非hla配對的人源化nsg小鼠模式 |
| WO2017040930A2 (en) | 2015-09-03 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Biomarkers predictive of cytokine release syndrome |
| CN110099998A (zh) * | 2016-10-26 | 2019-08-06 | 艾欧凡斯生物治疗公司 | 冷冻保存的肿瘤浸润淋巴细胞的再刺激 |
| WO2018102546A1 (en) | 2016-11-30 | 2018-06-07 | The Jackson Laboratory | Humanized mouse model with improved human innate immune cell development |
| US11959925B2 (en) | 2017-04-17 | 2024-04-16 | The Jackson Laboratory | Method of determining toxicity of an immunomodulatory drug for use in humans |
| US11778994B2 (en) * | 2017-05-12 | 2023-10-10 | The Jackson Laboratory | NSG mice lacking MHC class I and class II |
| US20190091310A1 (en) * | 2017-09-26 | 2019-03-28 | Stephen E. Wright | Nonreleased il-12 for therapy of cancer |
| US11712026B2 (en) | 2017-10-18 | 2023-08-01 | The Jackson Laboratory | Murine-MHC-deficient HLA-transgenic nod-mouse models for T1D therapy development |
| WO2019084018A1 (en) * | 2017-10-23 | 2019-05-02 | City Of Hope | CAR FOR THE TREATMENT OF HIV INFECTION |
| CN110055223A (zh) * | 2018-01-19 | 2019-07-26 | 北京百奥赛图基因生物技术有限公司 | 一种B2m基因改造的免疫缺陷动物的制备方法及其应用 |
| US20210214723A1 (en) * | 2018-06-01 | 2021-07-15 | Mayo Foundation For Medical Education And Research | Materials and methods for treating cancer |
| WO2020206149A2 (en) * | 2019-04-05 | 2020-10-08 | The Regents Of The University Of California | Methods and compositions involving chimeric binding polypeptides |
-
2021
- 2021-09-23 AU AU2021347320A patent/AU2021347320A1/en active Pending
- 2021-09-23 IL IL301634A patent/IL301634A/en unknown
- 2021-09-23 CA CA3196823A patent/CA3196823A1/en active Pending
- 2021-09-23 JP JP2023518849A patent/JP2023542539A/ja active Pending
- 2021-09-23 KR KR1020237013626A patent/KR20230074758A/ko active Pending
- 2021-09-23 WO PCT/US2021/051734 patent/WO2022066894A1/en not_active Ceased
- 2021-09-23 EP EP21873419.2A patent/EP4216971A4/en active Pending
-
2022
- 2022-03-25 US US17/705,037 patent/US12196744B2/en active Active
-
2024
- 2024-12-06 US US18/972,072 patent/US20250164467A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023542539A (ja) | 2023-10-10 |
| AU2021347320A1 (en) | 2023-05-11 |
| CA3196823A1 (en) | 2022-03-31 |
| US12196744B2 (en) | 2025-01-14 |
| WO2022066894A1 (en) | 2022-03-31 |
| EP4216971A1 (en) | 2023-08-02 |
| US20220214330A1 (en) | 2022-07-07 |
| US20250164467A1 (en) | 2025-05-22 |
| EP4216971A4 (en) | 2024-10-02 |
| KR20230074758A (ko) | 2023-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12196744B2 (en) | Humanized mouse models for assessing immune cell therapy | |
| US20260115284A1 (en) | Toxicity management for anti-tumor activity of cars | |
| CN112469829B (zh) | 包含抗gpc3单链抗体的car | |
| US20200182880A1 (en) | Cancer antigen targets and uses thereof | |
| RU2770002C2 (ru) | Химерный антигенный рецептор | |
| CN110573180A (zh) | 癌症治疗用药物组合物 | |
| JP2018522907A5 (cg-RX-API-DMAC7.html) | ||
| EP3757133A1 (en) | Isolated chimeric antigen receptor, modified t cell comprising same and use thereof | |
| Rodriguez et al. | Antitumor activity of a novel LAIR1 antagonist in combination with anti-PD1 to treat collagen-rich solid tumors | |
| Tirado et al. | CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia | |
| US20250369955A1 (en) | Mouse models of cytokine release syndrome | |
| CN119522238A (zh) | 免疫效应细胞及其应用 | |
| CN117777289B (zh) | 靶向cldn18.2的人源化抗体、衍生产品及其在肿瘤治疗中的应用 | |
| JP2026513920A (ja) | リンホトキシンベータ受容体アゴニストを用いてがんを処置する方法 | |
| CN116916748A (zh) | 用于评估免疫细胞疗法的人源化小鼠模型 | |
| US12329814B2 (en) | Combination of a substance modulating tumor immune microenvironment and immunotherapy for the treatment of cancer | |
| HK40069741A (en) | Toxicity management for anti-tumor activity of cars | |
| HK40039113A (en) | Toxicity management for anti-tumor activity of cars | |
| HK1253365B (en) | Toxicity management for anti-tumor activity of cars | |
| CN121548589A (zh) | 细胞免疫疗法的组合物和方法 | |
| EA041322B1 (ru) | Контроль над токсичностью в случае противоопухолевой активности химерных антигенных рецепторов (car) |